RATIONALE: Specialized radiation therapy that delivers radiation directly to the area where a tumor was surgically removed may kill any remaining tumor cells and cause less damage to normal tissue. PURPOSE: This phase I/II trial is studying radiation therapy to see how well it works in treating patients who are undergoing surgery to remove a metastatic brain tumor.
OBJECTIVES: Primary * Determine the 1-year local control rate in patients undergoing resection of a solitary brain metastasis comprising intraoperative radiotherapy using the INTRABEAM® system. Secondary * Determine the survival of patients treated with this therapy. * Determine distant recurrence of disease in patients treated with this therapy. * Determine the toxicity of this therapy in these patients. * Determine the quality of life of patients treated with this therapy. OUTLINE: This is a nonrandomized study. Patients undergo surgical resection of a brain metastasis. Patients then undergo intraoperative radiotherapy using the INTRABEAM® system. Quality of life is assessed at baseline and then every 3 months for 2 years. Patients are followed within 48 hours after surgery, at 1 and 3 months, and then every 3 months for 2 years. PROJECTED ACCRUAL: A total of 31-62 patients will be accrued for this study.
Study Type
INTERVENTIONAL
Purpose
TREATMENT
Masking
NONE
Enrollment
62
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, United States
RECRUITINGLocal control rate as measured by MRI with contrast at 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.